#Coronavirus Disease Research #References (by AMEDEO, April 12 '25)

 

Br J Anaesth

1. GILLIS C, Hasil L, Keane C, Brassard D, et al
   A multimodal prehabilitation class for Enhanced Recovery After Surgery: a pragmatic randomised type 1 hybrid effectiveness-implementation trial.
   Br J Anaesth. 2025 Apr 7:S0007-0912(25)00153-9. doi: 10.1016/j.bja.2025.
   PubMed         Abstract available
   
   

   
   Clin Infect Dis

2. IOANNOU GN, Berry K, Rajeevan N, Li Y, et al
   Target Trial Emulation of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Versus No Infection and Risk of Post-Coronavirus Disease 2019 Conditions in the Omicron Variant Versus Prior Eras.
   Clin Infect Dis. 2025 Apr 10:ciaf087. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

3. JOLLIVET O, Urchueguia-Fornes A, Chung-Delgado K, Johannesen CK, et al
   Respiratory Syncytial Virus hospitalisation burden in children below 18 years in six European countries (2016-2023) pre- and post-COVID-19 pandemic.
   Int J Infect Dis. 2025 Apr 7:107903. doi: 10.1016/j.ijid.2025.107903.
   PubMed         Abstract available
   
   

   
   J Med Virol

4. LIU J, Guo L, Zhong J, Wu Y, et al
   Proteomic Analysis of 442 Clinical Plasma Samples From Individuals With Symptom Records Revealed Subtypes of Convalescent Patients Who Had COVID-19.
   J Med Virol. 2025;97:e70203.
   PubMed         Abstract available
   
   
5. ZHANG Y, Pu D, Liu Q, Li B, et al
   Epidemic Outbreak of Respiratory Syncytial Virus Infection After the end of the Zero-COVID-19 Policy in China: Molecular Characterization and Disease Severity Associated With a Novel RSV-B Clade.
   J Med Virol. 2025;97:e70343.
   PubMed         Abstract available
   
   
6. GUSTANI-BUSS E, Buss CE, Biagi CAO, Oliveira IM, et al
   Unveiling the Dynamics of SARS-CoV-2 Gamma and Delta Waves in Parana, Brazil - Delta Displacing a Persistent Gamma Through Alternative Routes of Dispersal.
   J Med Virol. 2025;97:e70318.
   PubMed         Abstract available
   
   
7. SUN P, Liu Q, Yuan S, Wang XT, et al
   SARS-CoV-2 Membrane Protein Induces MARCHF1/GPX4-Mediated Ferroptosis by Promoting Lipid Accumulation.
   J Med Virol. 2025;97:e70328.
   PubMed         Abstract available
   
   

   
   J Travel Med

8. PATEL P, Freedman DO
   Considerations for prevention and standby emergency treatment for travellers at high- risk of COVID-19 hospitalization.
   J Travel Med. 2025 Apr 4:taaf029. doi: 10.1093.
   PubMed        
   
   

   
   J Virol

9. ZHOU B, Gui Q, Liu C, Guo H, et al
   Structure and function of an unusual R452-dependent monoclonal antibody against SARS-CoV-2.
   J Virol. 2025 Apr 8:e0184424. doi: 10.1128/jvi.01844.
   PubMed         Abstract available
   
   

   
   Lancet

10. SUN L, Selbie D, Khan AS, Karim SSA, et al
    Mobilising national and regional assets and non-state actors for pandemic preparedness.
    Lancet. 2025 Apr 3:S0140-6736(25)00630-0. doi: 10.1016/S0140-6736(25)00630.
    PubMed        
    
    
11. YUNAS I, Islam MA, Sindhu KN, Devall AJ, et al
    Causes of and risk factors for postpartum haemorrhage: a systematic review and meta-analysis.
    Lancet. 2025 Apr 3:S0140-6736(25)00448-9. doi: 10.1016/S0140-6736(25)00448.
    PubMed         Abstract available
    
    

    
    Lancet Infect Dis

12. CHODICK G
    Long-term infectious sequelae after SARS-CoV-2 infection should be considered in mild cases too.
    Lancet Infect Dis. 2025 Apr 1:S1473-3099(25)00074.
    PubMed        
    
    
13. BEJON P, Agweyu A, Ochola-Oyier LI, Hamaluba M, et al
    Rethinking the evidence on COVID-19 in Africa.
    Lancet Infect Dis. 2025 Apr 4:S1473-3099(25)00071.
    PubMed         Abstract available
    
    
14. SAWANO M, Bhattacharjee B, Caraballo C, Khera R, et al
    Nirmatrelvir-ritonavir versus placebo-ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial.
    Lancet Infect Dis. 2025 Apr 3:S1473-3099(25)00073.
    PubMed         Abstract available
    
    
15. CAI M, Xu E, Xie Y, Al-Aly Z, et al
    Rates of infection with other pathogens after a positive COVID-19 test versus a negative test in US veterans (November, 2021, to December, 2023): a retrospective cohort study.
    Lancet Infect Dis. 2025 Apr 1:S1473-3099(24)00831.
    PubMed         Abstract available
    
    

    
    Life Sci

16. AZEEM M, Cancemi P, Mukhtar F, Marino S, et al
    Efficacy and limitations of SARS-CoV-2 vaccines - A systematic review.
    Life Sci. 2025;371:123610.
    PubMed         Abstract available
    
    

    
    Nature

17. THOMPSON B
    From Hippocrates to COVID-19: the scientific fight to prove diseases can be airborne.
    Nature. 2025 Apr 7. doi: 10.1038/d41586-025-00960.
    PubMed        
    
    
18. LEDFORD H, Kozlov M
    Long COVID activists fought Trump team's research cuts and won - for now.
    Nature. 2025 Apr 7. doi: 10.1038/d41586-025-00995.
    PubMed        
    
    

    
    Science

19. KAISER J
    Health agencies reeling as leaders, staff slashed.
    Science. 2025;388:134-135.
    PubMed         Abstract available
    
    
20. JOOSTE I
    No one can replace the U.S. as it retreats from global health.
    Science. 2025;388:138-139.
    PubMed         Abstract available